PubMed Health⌕ Search

Biomedical subjects

R Lingeman

Publications and source records attributed to R Lingeman.

5 recordsLinked to original sources
PubMed1990

Prosthetic and surgical management of osteogenic sarcoma of the maxilla.

Maxillary surgical defects resulting from resection of oral neoplasms vary in size from small perforations of the hard and soft palate to complete removal of these structures. Osteogenic sarcoma is of unknown etiology and is a rapidly growing tumor that may produce pain, paresthesia, and anesthesia. The recommended treatment of radical resection often results in defects that produce significant orofacial disfigurement. These defects, regardless of size, present significant functional disability, with compromised esthetics, mastication, and deglutition. Restoration with a maxillary obturator prosthesis can reestablish the physical separation between oral and nasal cavities and, in soft palate defects, enable normal palatopharyngeal function. Most patients can be rehabilitated successfully with restoration of speech and swallowing to normal levels and significant improvement in appearance.

Deglutition Disorders↗
PubMed1985

Extranodal lymphoma of the head and neck area.

Records of 64 patients with extranodal lymphoma of the head and neck area treated at this institution between 1965 and 1982 have been reviewed. Of these cases, 78% had Stage I-EA disease, 20% had Stage II-EA disease, and 2% had Stage III-EA disease. Excluded from this study were patients of the pediatric age, patients with previous chemotherapy and surgery, patients in whom extranodal involvement has been a terminal manifestation of wide-spread disease, and patients with nodal involvement with extension of disease outside the lymph nodes. Patients with a histiocytic histology accounted for 63%, 28% were of lymphocytic histologies, 4.5% were of mixed histologies, and in 4.5% a diagnosis of lymphoma or benign lymphocytic proliferation had been made. The paranasal sinuses, nasal cavity, and oral cavity were the most frequent sites of involvement, making up 39% of the cases--with the orbit, central nervous system, nasopharynx, salivary glands, thyroid, skin, and larynx following in that order of frequency. All patients received a definitive course of radiotherapy, except patients with CNS involvement. In no case was chemotherapy given concomitantly with the radiation therapy. One-third of the patients did require chemotherapy at a later time for progression of disease. No patients were lost to follow-up. Seven patients with primaries of the brain were inevaluable for response; however, all patients having visible or palpable tumors achieved a complete response (100%), and there was no recurrence or persistent disease in the field of therapy. The next area of disease involvement depended on the site of the primary. Nodal involvement following extranodal disease carried a poor prognosis.

Adult↗
PubMed1984

The role of radiation therapy in the treatment of malignant tumors of the paranasal sinuses.

During a 20 year period, 121 patients with malignant tumors of the paranasal sinuses were seen at this institution. Of these cases, 109 patients with carcinomas originating from the mucous or paranasal sinuses were evaluated. Data were analyzed on the basis of 1. primary tumor control and metastatic nodal sterilization, 2. pre and post-therapy incidence and location of neck node metastasis, and 3. overall survival. Data were also analyzed as to survival on the basis of TNM classification and histology. From this retrospective study, the incidence of neck node metastasis prior to treatment appears to be slightly higher than in literature (23/88 or 26%). The incidence of post-treatment metastasis is 9/88 or 10%. No significant correlation was noted between histology and neck node metastasis.

Adolescent↗
PubMed1980

Carcinoma of major salivary glands.

Ninety-four patients with carcinoma of the major salivary glands seen at Indiana University Hospitals from 1960-1977 were studied. Eighty-four patients completed their planned course of therapy, and 49 of 84 patients remain alive with no evidence of disease 2-17 years following treatment. Comparison has been made for three modalities: surgery alone, radiation therapy alone, and a combined approach. Surgery alone was used for treatment of early lesions, and 22 of 38 patients (58%) remain free of disease. Radiation therapy alone was used for advanced cases and palliation, and 6 of 16 patients (37.5%) remain free of disease. In the combination treatment, 21 of 30 patients (70%) are alive and free of disease. In the combination treatment, 21 of 30 patients (70%) are alive and free of disease from 2-17 years after treatment. Ten patients did not complete treatment and all of these patients died of disease.

Adenocarcinoma↗